Curtis Ruegg, EVP R&D and Technology Operations at Revance Therapeutics, Inc. (RVNC), sold 1,500 shares at $18.50 ($28K) on 2014-10-17, disclosed to the SEC on 2014-10-21.
Scheduled sale ($28k) by EVP R&D and Technology Operations under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $18.50 | 500 | $9K | 33.2% |
| 2 | $18.59 | 1,000 | $19K | 66.8% |
| Total | $18.56 avg | 1,500 | $28K | 100% |
| Filing → |
| RVNC | SELL | 2016-04-13 | $19K | — | Filing → |
| RVNC | SELL | 2016-03-09 | $20K | — | Filing → |
| RVNC | SELL | 2016-02-10 | $18K | — | Filing → |